Halotestin 5 mg

• Halotestin 5 mg
• Brand: Magnus Pharmaceuticals
• Content: 100 tablets | 5 mg per tablet
• Manufactured in: Europe

Product Overview

Halotestin 5 mg provides fluoxymesterone, a potent 17--alkylated, 9-fluoro androgenic steroid with roughly 5 the androgen-receptor (AR) affinity of testosterone. It’s a gold standard in strength-focused AAS research, particularly for muscle-performance modeling, neural drive stimulation, and non-estrogenic lean-mass retention.

Its small 5 mg dosing allows precision micro-administration in both low- and high-resolution sampling models. With ~100% oral bioavailability and a mean half-life of 9 hours, Halotestin is ideal for acute PK/PD trials involving strength output, aggression, and hormonal modulation—without estrogen conversion.

Key Research Highlights

Explosive strength modeling: ~5 AR binding vs. testosterone supports peak-force output studies

Zero aromatisation: No estrogenic conversion — ideal for lean-gain without gynecomastia risks

Neural & aggression activation: Reported increases in CNS stimulation and workout aggression

Hepatic monitoring required: High risk of cholestatic jaundice and liver stress beyond 20 mg/day

WADA S1 banned: Any exposure yields a positive anti-doping result

Suggested Laboratory Applications

Androgen-receptor pathway modeling

Non-estrogenic strength gain simulations

Lean muscle maintenance in caloric-restriction studies

CNS aggression and neural drive research

Hepatotoxicity and cholestasis mechanism analysis

Technical Specifications

Main Risks

Cholestatic liver injury, mood swings, HDL/LDL, hypertension

Total Active Compound

500 mg fluoxymesterone per carton (5 mg 100 tablets)

Shelf-life

36 months (manufacturer specification)

Detection Window

7 days; LC-MS/MS detects long-term urinary metabolites

PubChem-Supported Research Insights

Fluoxymesterone increases maximal force output and lean-muscle density

Its non-aromatising structure eliminates estrogenic effects, such as fluid retention or gynecomastia

Stimulates androgen-driven CNS activity for enhanced aggression and neural activation

Documented use in androgen deficiency and ER+ cancer studies

Any fluoxymesterone exposure is a guaranteed WADA S1 violation

Documented Research Side Effects

Hepatocellular injury and cholestatic jaundice in extended protocols

Dyslipidaemia (HDL, LDL), acne, aggression, and hypertension

Elevated liver enzymes, especially >20 mg/day or 2+ weeks of use

Confirmed doping risk — banned across all tested competitive levels

Handling & Compliance

For Research Use Only — Not for human or veterinary useStore at 20–25°C, protect from light and moisturePurchase confirms qualified researcher statusListed on WADA Prohibited List S1 — any exposure triggers a positive test